Ascletis Pharma Management
Management criteria checks 2/4
Ascletis Pharma's CEO is Jinzi Jason Wu, appointed in Apr 2013, has a tenure of 11.08 years. total yearly compensation is CN¥22.58M, comprised of 99.5% salary and 0.5% bonuses, including company stock and options. directly owns 50.91% of the company’s shares, worth HK$721.77M. The average tenure of the management team and the board of directors is 3.2 years and 6.1 years respectively.
Key information
Jinzi Jason Wu
Chief executive officer
CN¥22.6m
Total compensation
| CEO salary percentage | 99.5% |
| CEO tenure | 11.1yrs |
| CEO ownership | 50.9% |
| Management average tenure | 3.2yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate
Dec 19
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Aug 23What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today
Nov 03Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth
Oct 13Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates
Aug 24Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
May 19Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts
Mar 27We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Feb 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥145m |
| Sep 30 2023 | n/a | n/a | -CN¥194m |
| Jun 30 2023 | n/a | n/a | -CN¥243m |
| Mar 31 2023 | n/a | n/a | -CN¥279m |
| Dec 31 2022 | CN¥23m | CN¥22m | -CN¥315m |
| Sep 30 2022 | n/a | n/a | -CN¥246m |
| Jun 30 2022 | n/a | n/a | -CN¥176m |
| Mar 31 2022 | n/a | n/a | -CN¥188m |
| Dec 31 2021 | CN¥20m | CN¥20m | -CN¥199m |
| Sep 30 2021 | n/a | n/a | -CN¥234m |
| Jun 30 2021 | n/a | n/a | -CN¥269m |
| Mar 31 2021 | n/a | n/a | -CN¥239m |
| Dec 31 2020 | CN¥11m | CN¥11m | -CN¥209m |
| Sep 30 2020 | n/a | n/a | -CN¥155m |
| Jun 30 2020 | n/a | n/a | -CN¥100m |
| Mar 31 2020 | n/a | n/a | -CN¥98m |
| Dec 31 2019 | CN¥11m | CN¥11m | -CN¥96m |
Compensation vs Market: Jinzi Jason's total compensation ($USD3.12M) is above average for companies of similar size in the Hong Kong market ($USD330.03K).
Compensation vs Earnings: Jinzi Jason's compensation has increased whilst the company is unprofitable.
CEO
Jinzi Jason Wu (59 yo)
11.1yrs
Tenure
CN¥22,584,000
Compensation
Dr. Jinzi Jason Wu Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScience Co., Ltd.a pharmace...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.1yrs | CN¥22.58m | 50.91% CN¥ 721.8m | |
| Senior VP of Operations & Executive Director | 3.2yrs | CN¥2.67m | 0.11% CN¥ 1.6m | |
| Senior Vice President of Clinical Development Operations | 3.2yrs | no data | no data | |
| Senior Consultant & Head of Discovery | 11yrs | no data | no data | |
| Senior Consultant & Chief Medical Advisor | 6.7yrs | no data | no data | |
| Chief Business Officer | 1.9yrs | no data | no data | |
| Company Secretary | 1.8yrs | no data | no data |
3.2yrs
Average Tenure
54yo
Average Age
Experienced Management: 1672's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.3yrs | CN¥22.58m | 50.91% CN¥ 721.8m | |
| Senior VP of Operations & Executive Director | 6.2yrs | CN¥2.67m | 0.11% CN¥ 1.6m | |
| Independent Non-Executive Director | 6.1yrs | CN¥384.00k | no data | |
| Independent Non-Executive Director | 6.1yrs | CN¥383.00k | no data | |
| Independent Non-Executive Director | 6.1yrs | CN¥383.00k | no data |
6.1yrs
Average Tenure
49yo
Average Age
Experienced Board: 1672's board of directors are considered experienced (6.1 years average tenure).